Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis
Archives of Gynecology and Obstetrics · 07.10.2024 · 311 (2) · 423-427
DOI: 10.1007/s00404-024-07761-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Archives of Gynecology and Obstetrics, online erschienen am 07.10.2024. Verfasst von Damian J Ralser und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Gynecological Oncology, University Hospital Bonn, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germa…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BONFOR, DFG, Universitätsklinikum Bonn.
Abstract (Originalsprache)
Purpose
CDK4/6 inhibitors (CDK4/6i) represent the first-line therapy approach of choice for patients with hormone receptor-positive, HER2-negative advanced breast cancer (HR + /HER-ABC). Approximately 50% of HR + /HER2-ABC displays low HER2 expression (HER2 low). Recent data emerging from the DESTINY-Breast04 trial demonstrated practice-changing efficacy of the antibody–drug conjugate trastuzumab deruxtecan (T-DXd) in patients with low HER2 expression. Here, we aimed to analyze the impact of low HER2 expression on CDK4/6i therapy response in a well-characterized multicenter HR + /HER-ABC cohort.
Methods
Patients diagnosed with HR + /HER2-ABC who were treated with CDK4/6i in clinical routine between November 2016 and December 2020 at four certified German Breast Cancer Centers were retrospectively identified. The cohort was stratified according to graduation of positivity in HER2 immunohistochemistry (IHC; HER2 zero = IHC score 0 and HER2 low = IHC score 1 + , 2 + /fluorescence in situ hybridization negative). Subgroups were analyzed with regard to progression-free survival (PFS) following CDK4/6i initiation.
Findings
The study cohort comprised n = 448 patients. For n = 311 patients, HER2 status from the metastatic site was available. n = 91 (29.3%) cases were HER2 zero and n = 220 cases (70.7%) were HER2 low. There was no significant difference in PFS between the two groups (PFS: 17 months versus 18 months, log-rank p = 0.42). Further, we examined the influence of HER2 expression changes between primary and metastatic tissue ( n = 171; HER2 gain/HER2 loss/HER2 stable expression) on CDK4/6i treatment response. Again, there was no significant difference between these three groups, respectively (PFS: 16 months versus 13 months versus 17 months, log-rank p = 0.86).
Conclusions
In our analysis, HER2 status did not have a significant impact on treatment response to CDK4/6i.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Gynecological Oncology, University Hospital Bonn, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. damian.ralser@ukbonn.de.
- Department of Gynecology With Breast Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
- Department of Gynecology, Obstetrics & Reproductive Medicine, Saarland University Medical Center, Homburg, Saar, Germany.
- Department of Gynecology and Gynecological Oncology, University Hospital Bonn, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
- Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.
- Department of Gynecology and Obstetrics, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany.
Förderung
- BONFOR
- DFG
- Universitätsklinikum Bonn
Zitieren
APA
Ralser, D. J., Kiver, V., Solomayer, E. F., Neeb, C., Blohmer, J. U., Abramian, A. V., Maass, N., Schütz, F., Kolberg-Liedtke, C., Müller, C., & Rambow, A. C. (2024). Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis. Archives of Gynecology and Obstetrics, 311(2), 423-427. https://doi.org/10.1007/s00404-024-07761-2
Vancouver
Ralser DJ, Kiver V, Solomayer EF, Neeb C, Blohmer JU, Abramian AV, et al. Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis. Archives of Gynecology and Obstetrics. 2024;311(2):423-427. doi:10.1007/s00404-024-07761-2
BibTeX
@article{Ralser2024,
author = {Ralser, Damian J and Kiver, Verena and Solomayer, Erich-Franz and Neeb, Caroline and Blohmer, Jens-Uwe and Abramian, Alina V and Maass, Nicolai and Schütz, Florian and Kolberg-Liedtke, Cornelia and Müller, Carolin and Rambow, Anna-Christina},
title = {Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis},
journal = {Archives of Gynecology and Obstetrics},
year = {2024},
volume = {311},
number = {2},
pages = {423--427},
doi = {10.1007/s00404-024-07761-2}
}
EUVIMED